Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 236

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 236
---
 any role to be performed by BofA in the proposed Business Combination. On September 28, 2022, BofA delivered to APx a notice waiving its entitlement to the payment of its deferred underwriting fee with respect to the Business Combination with the Company, declining to serve in any capacity in connection with the Business Combination with the Company, confirming that it does not have any role with respect to the Business Combination with the Company and disclaiming any responsibility for any portion of this proxy statement/prospectus. BofA communicated to APx its decision to waive its deferred underwriting fee with respect to the Business Combination was due to market and regulatory uncertainty relating to special purpose acquisition company business combination transactions in general BofA received no additional consideration for the waiver of its entitlement to the payment of the deferred underwriting fee with respect to the Business Combination. 97 APx believes that a gratuitous waiver of fees for services that have already been rendered is unusual, and some investors may find the Business Combination with the Company less attractive as a result. Public Shareholders should not put any reliance on the fact that BofA was previously engaged by APx to serve as an underwriter in the IPO and should not assume that BofA was involved in the Business Combination with the Company. This may make it more difficult for APx to complete the Business Combination with the Company. In addition, APx continues to have customary obligations under certain provisions of the underwriting agreement relating to the IPO. These provisions include the relevant clauses of the underwriters’ standard terms and conditions, including APx’s obligation to (i) indemnify and hold harmless each of the underwriters, the directors, officers, employees, affiliates and agents of each underwriter, and each person, if any, who controls any of the underwriters or any affiliate within the meaning of the Securities Act or the Exchange Act, against any and all losses, claims, damages or liabilities, joint or several, to which they or any of them may become subject under the Securities Act, the Exchange Act or other U.S. federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained in the registration statement for the registration of the securities sold in the IPO as originally filed or in any amendment thereof, or in any Preliminary Prospectus, the IPO Prospectus, any “road